Induvita Raises NOK 7.5M Seed for Women's-Health Medtech Devices

Induvita Secures NOK 7.5 Million in Seed Funding

Induvita, a Norwegian women's-health medtech company, has raised NOK 7.5 million in seed funding. The round was backed by Magisk Potet AS and Fan Wing AS.

What Induvita Does

Founded in 2022 in Bodø, Norway, Induvita develops medical devices and training simulators for gynecology and obstetrics. The company was established by midwife Hege Hansen and gynecologist Stine Andreasen, combining clinical practice with device development.

Its product portfolio spans examination, procedural and training needs:

• Runa and Ayla — examination simulators for gynecology and obstetrics training
• Vega — a single-use vaginal speculum, scheduled to launch in Europe in 2026
• Iola — a labor-induction catheter currently in development

Market Reach

Induvita's products are already sold across Europe, the USA and Australia, giving the company commercial traction in multiple regions ahead of the Vega launch.

Recognition

In 2025, Induvita was named Health Startup of the Year by Tekna and Norway Health Tech, an award that reflects its position within the Norwegian health-tech ecosystem.

Deal Summary

• Company: Induvita
• Sector: Women's-health medtech
• Headquarters: Bodø, Norway
• Founded: 2022
• Round type: Seed
• Amount raised: NOK 7.5 million
• Investors: Magisk Potet AS, Fan Wing AS
• Funding date: September 15, 2026

Why It Matters

Women's-health medtech has historically been underserved relative to its clinical footprint, and Induvita's combination of training simulators and single-use procedural devices addresses both education and clinical practice. The company's existing sales across three continents provides a foundation for scaling the upcoming Vega speculum launch in Europe.

For acquirers and strategic partners in medical devices, Induvita represents a clinically founded, internationally distributed platform with a defined product roadmap extending through 2026 and beyond.